Support The Moscow Times!

EU Medical Official Warns of Sputnik Jab 'Russian Roulette'

The head of the management board at the EU's medicines regulator warned late Sunday against emergency national authorizations of Russia's Sputnik V vaccine, comparing the idea to "Russian roulette".

Last week the Amsterdam-based European Medicines Agency (EMA) launched a rolling review of the Sputnik V vaccine, a key step towards being approved as the first non-Western jab to be used across the 27-nation bloc.

Hungary has already approved Sputnik V and started using it as part of its vaccine rollout, while the Czech Republic and Slovakia have also ordered doses and say they will not wait for EMA approval.

Asked about the prospect of Austria taking the same step, EMA management board chair Christa Wirthumer-Hoche told Austria's ORF broadcaster: "It's somewhat comparable to Russian roulette."

"I would strongly advise against a national emergency authorization," she said, pointing to the fact that there was not yet sufficient safety data about those who had already been given the vaccine.

"We could have Sputnik V on the market in future, when we've examined the necessary data," she said, adding that the vaccine needed to match up to European criteria on quality control and efficacy.

Austrian Chancellor Sebastian Kurz on Friday met the top Russian official in charge of marketing Sputnik V, and had previously emphasized that vaccine procurement should not be subject to "geopolitical struggles".

Kurz has said however that Austria will wait for EMA approval before using the vaccine.

Russia has said it is ready to provide jabs for 50 million Europeans as soon as Sputnik V gets the green light.

Moscow has pushed Europe to follow the lead of dozens of countries around the world that have approved Sputnik, but Brussels has been wary the Kremlin will use the vaccine as a soft-power tool.

The EU, which has been criticized for a slow start to its mass vaccination rollout, has so far authorized three vaccines: the US-German Pfizer/BioNTech jab, U.S. firm Moderna's shot, and the British-Swedish AstraZeneca/Oxford vaccine. 

It is set to decide on the one-shot Johnson & Johnson vaccine on March 11, while jabs by Novavax and CureVac are also under rolling review.

Sign up for our free weekly newsletter

Our weekly newsletter contains a hand-picked selection of news, features, analysiss and more from The Moscow Times. You will receive it in your mailbox every Friday. Never miss the latest news from Russia. Preview
Subscribers agree to the Privacy Policy

A Message from The Moscow Times:

Dear readers,

We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."

These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.

We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.

By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more